<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/8BF5398F-8876-4248-AFAA-FD0135C9E14A" ns1:id="8BF5398F-8876-4248-AFAA-FD0135C9E14A"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/108C0C97-5466-4813-8B9D-572A2E9B1A16" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/108C0C97-5466-4813-8B9D-572A2E9B1A16" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2013-10-31T00:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/066E0962-C23C-456B-8074-F35C05D3CA7E" ns1:rel="FUND" ns1:start="2013-03-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">131048</ns2:identifier></ns2:identifiers><ns2:title>Feasibility study for the development of a software platform for the design of stratified medicine and benefit-risk studies.</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Exploristics seek to explore and appraise the commerical potential for an innovative new simulation platform which will allow users to simulate and evaluate clinical studies with multiple objectives prior to their initiation, allowing determination of the optimal design and analysis approach to meet study objectives with the minimum number of patients, and therefore cost.
Exploristics believe that the future success of all clinical development of new drugs is fundamentally dependent on the application of correct study design, analysis strategy and decision criteria, given constraints. The platform will be particularly useful in development of personalised medicine and in assessing the benefit/risk of new treatments. It will be of interest to drug developers, data providers, diagnostics companies and to the Regulators.</ns2:abstractText></ns2:project>